June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Qualitative and quantitative changes of cystoid macular edema treated with Ozurdex therapy
Author Affiliations & Notes
  • Raeba Mathew
    Ophthalmology, King's College Hospital, London, London, United Kingdom
  • Elizabeth Pearce
    Ophthalmology, King's College Hospital, London, London, United Kingdom
    Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Sobha Sivaprasad
    Ophthalmology, King's College Hospital, London, London, United Kingdom
    Ophthalmology, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Raeba Mathew, Allergan (R), Novartis (R); Elizabeth Pearce, Novartis (R); Sobha Sivaprasad, Allergan (F), Bayer (F), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4898. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Raeba Mathew, Elizabeth Pearce, Sobha Sivaprasad, ; Qualitative and quantitative changes of cystoid macular edema treated with Ozurdex therapy. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4898.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe progression, resolution and relapse of cystoid macular edema (CME) over 9 months following Ozurdex therapy, to understand the prognostic values of various morphological features of CME.

Methods: Twenty-eight eyes with cystoid macular edema were examined at monthly intervals to assess the resolution and relapse of macular edema following Ozurdex therapy in a prospective study. The quantitative measures included central retinal thickness (CRT), central subfield thickness (CST), macular volume, number of zones with >300um, the foveal, parafoveal and perifoveal distribution of edema at monthly intervals. The qualitative measures included the presence, resolution and reappearance of cysts in different layers at each time points. Other structural changes included the persistence of foveal ellipsoid layer and external limiting membrane. Applying repeated-measures ANOVA, morphological findings were evaluated as predictive factors for relapse free period and treatment outcome.

Results: At baseline, all patients presented with cystoid edema. 60.7% had both outer nuclear layer/Henle's-layer (ONL/HL), 21% had ONL cysts only and the rest had only inner nuclear layer (INL) cysts. Following Ozurdex therapy, ONL/HL-cysts diminished before INL-cysts (p=0.0008). Subretinal fluid disappeared in all cases by 3 months and recurrence in these cases were dominated by INL cysts. Subretinal fluid recurred in 31% of cases. SRD at baseline predicted a relapse-free clinical-course within the 9 months period (p=0.025).

Conclusions: Different morphologic patterns in CME resolve and relapse at different time-points and may represent different stages of disease progression.

Keywords: 688 retina • 552 imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×